Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

NCT06138613 · tracked via the Priya Life Science USA tracker

Sponsor

Vanda Pharmaceuticals

Phase

Phase 3

Started

2023-02-27

Last updated

2026-04-16

Condition(s) studied

Motion Sickness

Investigational drug(s) / intervention(s)

Tradipitant

Tradipitant: Oral Capsule

Study summary

An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * History of Motion Sickness * Age 18-75 Exclusion Criteria: * Nausea-inducing disorder other than motion sickness * BMI \> 40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Primary outcome measure(s)

Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs). — through study completion, approximately 1 year
Safety will be monitored using clinical measures, vital signs, blood chemistry, hematology, urology, and ECGs.

Trial sites (1)

Facility	City	Region	Status
Santa Monica Clinical Trials	Santa Monica	California

More Vanda Pharmaceuticals trials in the USA

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Active, not recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting

Patient Registry of Blind Subjects With Sleep-related Problems Recruiting

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06138613 on ClinicalTrials.gov ↗ ← All trials in the USA